Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

Jounce Therapeutics logo

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Advanced Chart

Key Stats

Today's Range
$1.88
$1.88
50-Day Range
$1.84
$1.94
52-Week Range
$0.58
$5.87
Volume
169,314 shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNCE Stock News Headlines

What The Silver Boom Could Mean For You…
AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-overlooked metal isn’t just about “green tech” anymore — it’s becoming critical to the AI revolution and modern energy systems. A new report explains why silver may be one of the most undervalued assets in the market today, and how everyday investors can use it to diversify and protect their savings. It also outlines a simple IRS-approved strategy that makes owning silver easier than most people realize.tc pixel
See More Headlines

JNCE Stock Analysis - Frequently Asked Questions

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15.

Jounce Therapeutics (JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/04/2021
Today
9/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JNCE
CIK
1640455
Fax
N/A
Employees
137
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.92 million
Net Margins
N/A
Pretax Margin
-61.93%
Return on Equity
-30.90%
Return on Assets
-26.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.37
Quick Ratio
8.37

Sales & Book Value

Annual Sales
$82 million
Price / Sales
1.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.54 per share
Price / Book
0.53

Miscellaneous

Outstanding Shares
52,630,000
Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:JNCE) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners